img

Global Immuno-oncology Drugs Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Immuno-oncology Drugs Market Insights, Forecast to 2034

Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.
Market Analysis and InsightsGlobal Immuno-oncology Drugs Market
Global Immuno-oncology Drugs market is expected to reach to US$ 20480 million in 2024, with a positive growth of %, compared with US$ 17500 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Immuno-oncology Drugs industry is evaluated to reach US$ 51870 million in 2029. The CAGR will be 16.8% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Immuno-oncology Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Immuno-oncology Drugs market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Dendreon Corporation
Agilent Technologies Inc.
Agenus Inc.
Enzo Biochem, Inc.
Lonza Group
Bio-Rad Laboratories, Inc.
Avantor, Inc.
Spring Bank Pharmaceuticals, Inc.
Ferring Pharmaceuticals
Segment by Type
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others

Segment by Application


Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Immuno-oncology Drugs introduction, etc. Immuno-oncology Drugs Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Immuno-oncology Drugs
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immuno-oncology Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Immune System Modulators
1.2.4 Cancer Vaccines
1.2.5 Oncolytic Virus
1.2.6 Others
1.3 Market by Application
1.3.1 Global Immuno-oncology Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immuno-oncology Drugs Market Perspective (2018-2029)
2.2 Global Immuno-oncology Drugs Growth Trends by Region
2.2.1 Immuno-oncology Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Immuno-oncology Drugs Historic Market Size by Region (2018-2024)
2.2.3 Immuno-oncology Drugs Forecasted Market Size by Region (2024-2029)
2.3 Immuno-oncology Drugs Market Dynamics
2.3.1 Immuno-oncology Drugs Industry Trends
2.3.2 Immuno-oncology Drugs Market Drivers
2.3.3 Immuno-oncology Drugs Market Challenges
2.3.4 Immuno-oncology Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Immuno-oncology Drugs by Players
3.1.1 Global Immuno-oncology Drugs Revenue by Players (2018-2024)
3.1.2 Global Immuno-oncology Drugs Revenue Market Share by Players (2018-2024)
3.2 Global Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Immuno-oncology Drugs, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Immuno-oncology Drugs Market Concentration Ratio
3.4.1 Global Immuno-oncology Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immuno-oncology Drugs Revenue in 2022
3.5 Global Key Players of Immuno-oncology Drugs Head office and Area Served
3.6 Global Key Players of Immuno-oncology Drugs, Product and Application
3.7 Global Key Players of Immuno-oncology Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Immuno-oncology Drugs Breakdown Data by Type
4.1 Global Immuno-oncology Drugs Historic Market Size by Type (2018-2024)
4.2 Global Immuno-oncology Drugs Forecasted Market Size by Type (2024-2029)
5 Immuno-oncology Drugs Breakdown Data by Application
5.1 Global Immuno-oncology Drugs Historic Market Size by Application (2018-2024)
5.2 Global Immuno-oncology Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Immuno-oncology Drugs Market Size (2018-2029)
6.2 North America Immuno-oncology Drugs Market Size by Type
6.2.1 North America Immuno-oncology Drugs Market Size by Type (2018-2024)
6.2.2 North America Immuno-oncology Drugs Market Size by Type (2024-2029)
6.2.3 North America Immuno-oncology Drugs Market Share by Type (2018-2029)
6.3 North America Immuno-oncology Drugs Market Size by Application
6.3.1 North America Immuno-oncology Drugs Market Size by Application (2018-2024)
6.3.2 North America Immuno-oncology Drugs Market Size by Application (2024-2029)
6.3.3 North America Immuno-oncology Drugs Market Share by Application (2018-2029)
6.4 North America Immuno-oncology Drugs Market Size by Country
6.4.1 North America Immuno-oncology Drugs Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Immuno-oncology Drugs Market Size by Country (2018-2024)
6.4.3 North America Immuno-oncology Drugs Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Immuno-oncology Drugs Market Size (2018-2029)
7.2 Europe Immuno-oncology Drugs Market Size by Type
7.2.1 Europe Immuno-oncology Drugs Market Size by Type (2018-2024)
7.2.2 Europe Immuno-oncology Drugs Market Size by Type (2024-2029)
7.2.3 Europe Immuno-oncology Drugs Market Share by Type (2018-2029)
7.3 Europe Immuno-oncology Drugs Market Size by Application
7.3.1 Europe Immuno-oncology Drugs Market Size by Application (2018-2024)
7.3.2 Europe Immuno-oncology Drugs Market Size by Application (2024-2029)
7.3.3 Europe Immuno-oncology Drugs Market Share by Application (2018-2029)
7.4 Europe Immuno-oncology Drugs Market Size by Country
7.4.1 Europe Immuno-oncology Drugs Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Immuno-oncology Drugs Market Size by Country (2018-2024)
7.4.3 Europe Immuno-oncology Drugs Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Immuno-oncology Drugs Market Size (2018-2029)
8.2 China Immuno-oncology Drugs Market Size by Type
8.2.1 China Immuno-oncology Drugs Market Size by Type (2018-2024)
8.2.2 China Immuno-oncology Drugs Market Size by Type (2024-2029)
8.2.3 China Immuno-oncology Drugs Market Share by Type (2018-2029)
8.3 China Immuno-oncology Drugs Market Size by Application
8.3.1 China Immuno-oncology Drugs Market Size by Application (2018-2024)
8.3.2 China Immuno-oncology Drugs Market Size by Application (2024-2029)
8.3.3 China Immuno-oncology Drugs Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Immuno-oncology Drugs Market Size (2018-2029)
9.2 Asia Immuno-oncology Drugs Market Size by Type
9.2.1 Asia Immuno-oncology Drugs Market Size by Type (2018-2024)
9.2.2 Asia Immuno-oncology Drugs Market Size by Type (2024-2029)
9.2.3 Asia Immuno-oncology Drugs Market Share by Type (2018-2029)
9.3 Asia Immuno-oncology Drugs Market Size by Application
9.3.1 Asia Immuno-oncology Drugs Market Size by Application (2018-2024)
9.3.2 Asia Immuno-oncology Drugs Market Size by Application (2024-2029)
9.3.3 Asia Immuno-oncology Drugs Market Share by Application (2018-2029)
9.4 Asia Immuno-oncology Drugs Market Size by Region
9.4.1 Asia Immuno-oncology Drugs Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Immuno-oncology Drugs Market Size by Region (2018-2024)
9.4.3 Asia Immuno-oncology Drugs Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Amgen, Inc
11.1.1 Amgen, Inc Company Details
11.1.2 Amgen, Inc Business Overview
11.1.3 Amgen, Inc Immuno-oncology Drugs Introduction
11.1.4 Amgen, Inc Revenue in Immuno-oncology Drugs Business (2018-2024)
11.1.5 Amgen, Inc Recent Developments
11.2 AstraZeneca, Plc
11.2.1 AstraZeneca, Plc Company Details
11.2.2 AstraZeneca, Plc Business Overview
11.2.3 AstraZeneca, Plc Immuno-oncology Drugs Introduction
11.2.4 AstraZeneca, Plc Revenue in Immuno-oncology Drugs Business (2018-2024)
11.2.5 AstraZeneca, Plc Recent Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Introduction
11.3.4 Bristol-Myers Squibb Revenue in Immuno-oncology Drugs Business (2018-2024)
11.3.5 Bristol-Myers Squibb Recent Developments
11.4 Celgene Corporation
11.4.1 Celgene Corporation Company Details
11.4.2 Celgene Corporation Business Overview
11.4.3 Celgene Corporation Immuno-oncology Drugs Introduction
11.4.4 Celgene Corporation Revenue in Immuno-oncology Drugs Business (2018-2024)
11.4.5 Celgene Corporation Recent Developments
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Immuno-oncology Drugs Introduction
11.5.4 Eli Lilly and Company Revenue in Immuno-oncology Drugs Business (2018-2024)
11.5.5 Eli Lilly and Company Recent Developments
11.6 Merck & Co.
11.6.1 Merck & Co. Company Details
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Immuno-oncology Drugs Introduction
11.6.4 Merck & Co. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.6.5 Merck & Co. Recent Developments
11.7 Hoffmann-La Roche AG
11.7.1 Hoffmann-La Roche AG Company Details
11.7.2 Hoffmann-La Roche AG Business Overview
11.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Introduction
11.7.4 Hoffmann-La Roche AG Revenue in Immuno-oncology Drugs Business (2018-2024)
11.7.5 Hoffmann-La Roche AG Recent Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Immuno-oncology Drugs Introduction
11.8.4 Johnson & Johnson Revenue in Immuno-oncology Drugs Business (2018-2024)
11.8.5 Johnson & Johnson Recent Developments
11.9 Novartis International AG
11.9.1 Novartis International AG Company Details
11.9.2 Novartis International AG Business Overview
11.9.3 Novartis International AG Immuno-oncology Drugs Introduction
11.9.4 Novartis International AG Revenue in Immuno-oncology Drugs Business (2018-2024)
11.9.5 Novartis International AG Recent Developments
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Details
11.10.2 AbbVie, Inc. Business Overview
11.10.3 AbbVie, Inc. Immuno-oncology Drugs Introduction
11.10.4 AbbVie, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.10.5 AbbVie, Inc. Recent Developments
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Company Details
11.11.2 Pfizer Inc. Business Overview
11.11.3 Pfizer Inc. Immuno-oncology Drugs Introduction
11.11.4 Pfizer Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.11.5 Pfizer Inc. Recent Developments
11.12 Sanofi S.A.
11.12.1 Sanofi S.A. Company Details
11.12.2 Sanofi S.A. Business Overview
11.12.3 Sanofi S.A. Immuno-oncology Drugs Introduction
11.12.4 Sanofi S.A. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.12.5 Sanofi S.A. Recent Developments
11.13 EMD Serono, Inc.
11.13.1 EMD Serono, Inc. Company Details
11.13.2 EMD Serono, Inc. Business Overview
11.13.3 EMD Serono, Inc. Immuno-oncology Drugs Introduction
11.13.4 EMD Serono, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.13.5 EMD Serono, Inc. Recent Developments
11.14 Gilead Sciences Inc.
11.14.1 Gilead Sciences Inc. Company Details
11.14.2 Gilead Sciences Inc. Business Overview
11.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Introduction
11.14.4 Gilead Sciences Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.14.5 Gilead Sciences Inc. Recent Developments
11.15 Prometheus Therapeutics & Diagnostics
11.15.1 Prometheus Therapeutics & Diagnostics Company Details
11.15.2 Prometheus Therapeutics & Diagnostics Business Overview
11.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Introduction
11.15.4 Prometheus Therapeutics & Diagnostics Revenue in Immuno-oncology Drugs Business (2018-2024)
11.15.5 Prometheus Therapeutics & Diagnostics Recent Developments
11.16 Aduro BioTech
11.16.1 Aduro BioTech Company Details
11.16.2 Aduro BioTech Business Overview
11.16.3 Aduro BioTech Immuno-oncology Drugs Introduction
11.16.4 Aduro BioTech Revenue in Immuno-oncology Drugs Business (2018-2024)
11.16.5 Aduro BioTech Recent Developments
11.17 Galena Biopharma
11.17.1 Galena Biopharma Company Details
11.17.2 Galena Biopharma Business Overview
11.17.3 Galena Biopharma Immuno-oncology Drugs Introduction
11.17.4 Galena Biopharma Revenue in Immuno-oncology Drugs Business (2018-2024)
11.17.5 Galena Biopharma Recent Developments
11.18 Bavarian Nordic
11.18.1 Bavarian Nordic Company Details
11.18.2 Bavarian Nordic Business Overview
11.18.3 Bavarian Nordic Immuno-oncology Drugs Introduction
11.18.4 Bavarian Nordic Revenue in Immuno-oncology Drugs Business (2018-2024)
11.18.5 Bavarian Nordic Recent Developments
11.19 Celldex Therapeutics
11.19.1 Celldex Therapeutics Company Details
11.19.2 Celldex Therapeutics Business Overview
11.19.3 Celldex Therapeutics Immuno-oncology Drugs Introduction
11.19.4 Celldex Therapeutics Revenue in Immuno-oncology Drugs Business (2018-2024)
11.19.5 Celldex Therapeutics Recent Developments
11.20 ImmunoCellular Therapeutics
11.20.1 ImmunoCellular Therapeutics Company Details
11.20.2 ImmunoCellular Therapeutics Business Overview
11.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Introduction
11.20.4 ImmunoCellular Therapeutics Revenue in Immuno-oncology Drugs Business (2018-2024)
11.20.5 ImmunoCellular Therapeutics Recent Developments
11.21 Incyte
11.21.1 Incyte Company Details
11.21.2 Incyte Business Overview
11.21.3 Incyte Immuno-oncology Drugs Introduction
11.21.4 Incyte Revenue in Immuno-oncology Drugs Business (2018-2024)
11.21.5 Incyte Recent Developments
11.22 Dendreon Corporation
11.22.1 Dendreon Corporation Company Details
11.22.2 Dendreon Corporation Business Overview
11.22.3 Dendreon Corporation Immuno-oncology Drugs Introduction
11.22.4 Dendreon Corporation Revenue in Immuno-oncology Drugs Business (2018-2024)
11.22.5 Dendreon Corporation Recent Developments
11.23 Agilent Technologies Inc.
11.23.1 Agilent Technologies Inc. Company Details
11.23.2 Agilent Technologies Inc. Business Overview
11.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Introduction
11.23.4 Agilent Technologies Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.23.5 Agilent Technologies Inc. Recent Developments
11.24 Agenus Inc.
11.24.1 Agenus Inc. Company Details
11.24.2 Agenus Inc. Business Overview
11.24.3 Agenus Inc. Immuno-oncology Drugs Introduction
11.24.4 Agenus Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.24.5 Agenus Inc. Recent Developments
11.25 Enzo Biochem, Inc.
11.25.1 Enzo Biochem, Inc. Company Details
11.25.2 Enzo Biochem, Inc. Business Overview
11.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Introduction
11.25.4 Enzo Biochem, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.25.5 Enzo Biochem, Inc. Recent Developments
11.26 Lonza Group
11.26.1 Lonza Group Company Details
11.26.2 Lonza Group Business Overview
11.26.3 Lonza Group Immuno-oncology Drugs Introduction
11.26.4 Lonza Group Revenue in Immuno-oncology Drugs Business (2018-2024)
11.26.5 Lonza Group Recent Developments
11.27 Bio-Rad Laboratories, Inc.
11.27.1 Bio-Rad Laboratories, Inc. Company Details
11.27.2 Bio-Rad Laboratories, Inc. Business Overview
11.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Introduction
11.27.4 Bio-Rad Laboratories, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.27.5 Bio-Rad Laboratories, Inc. Recent Developments
11.28 Avantor, Inc.
11.28.1 Avantor, Inc. Company Details
11.28.2 Avantor, Inc. Business Overview
11.28.3 Avantor, Inc. Immuno-oncology Drugs Introduction
11.28.4 Avantor, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.28.5 Avantor, Inc. Recent Developments
11.29 Spring Bank Pharmaceuticals, Inc.
11.29.1 Spring Bank Pharmaceuticals, Inc. Company Details
11.29.2 Spring Bank Pharmaceuticals, Inc. Business Overview
11.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Introduction
11.29.4 Spring Bank Pharmaceuticals, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024)
11.29.5 Spring Bank Pharmaceuticals, Inc. Recent Developments
11.30 Ferring Pharmaceuticals
11.30.1 Ferring Pharmaceuticals Company Details
11.30.2 Ferring Pharmaceuticals Business Overview
11.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Introduction
11.30.4 Ferring Pharmaceuticals Revenue in Immuno-oncology Drugs Business (2018-2024)
11.30.5 Ferring Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Immuno-oncology Drugs Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Immune Checkpoint Inhibitors
Table 3. Key Players of Immune System Modulators
Table 4. Key Players of Cancer Vaccines
Table 5. Key Players of Oncolytic Virus
Table 6. Key Players of Others
Table 7. Global Immuno-oncology Drugs Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 8. Global Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Immuno-oncology Drugs Market Size by Region (2018-2024) & (US$ Million)
Table 10. Global Immuno-oncology Drugs Market Share by Region (2018-2024)
Table 11. Global Immuno-oncology Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Immuno-oncology Drugs Market Share by Region (2024-2029)
Table 13. Immuno-oncology Drugs Market Trends
Table 14. Immuno-oncology Drugs Market Drivers
Table 15. Immuno-oncology Drugs Market Challenges
Table 16. Immuno-oncology Drugs Market Restraints
Table 17. Global Immuno-oncology Drugs Revenue by Players (2018-2024) & (US$ Million)
Table 18. Global Immuno-oncology Drugs Revenue Share by Players (2018-2024)
Table 19. Global Top Immuno-oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2022)
Table 20. Global Immuno-oncology Drugs Industry Ranking 2021 VS 2022 VS 2024
Table 21. Global 5 Largest Players Market Share by Immuno-oncology Drugs Revenue (CR5 and HHI) & (2018-2024)
Table 22. Global Key Players of Immuno-oncology Drugs, Headquarters and Area Served
Table 23. Global Key Players of Immuno-oncology Drugs, Product and Application
Table 24. Global Key Players of Immuno-oncology Drugs, Product and Application
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Immuno-oncology Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 27. Global Immuno-oncology Drugs Revenue Market Share by Type (2018-2024)
Table 28. Global Immuno-oncology Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Immuno-oncology Drugs Revenue Market Share by Type (2024-2029)
Table 30. Global Immuno-oncology Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 31. Global Immuno-oncology Drugs Revenue Share by Application (2018-2024)
Table 32. Global Immuno-oncology Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Immuno-oncology Drugs Revenue Share by Application (2024-2029)
Table 34. North America Immuno-oncology Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 35. North America Immuno-oncology Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 36. North America Immuno-oncology Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 37. North America Immuno-oncology Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 38. North America Immuno-oncology Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 39. North America Immuno-oncology Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 40. North America Immuno-oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 41. Europe Immuno-oncology Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 42. Europe Immuno-oncology Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 43. Europe Immuno-oncology Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 44. Europe Immuno-oncology Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 45. Europe Immuno-oncology Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Europe Immuno-oncology Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 47. Europe Immuno-oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 48. China Immuno-oncology Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 49. China Immuno-oncology Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 50. China Immuno-oncology Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 51. China Immuno-oncology Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 52. Asia Immuno-oncology Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 53. Asia Immuno-oncology Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 54. Asia Immuno-oncology Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 55. Asia Immuno-oncology Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 56. Asia Immuno-oncology Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 57. Asia Immuno-oncology Drugs Market Size by Region (2018-2024) & (US$ Million)
Table 58. Asia Immuno-oncology Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Immuno-oncology Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 64. Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 65. Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 66. Amgen, Inc Company Details
Table 67. Amgen, Inc Business Overview
Table 68. Amgen, Inc Immuno-oncology Drugs Product
Table 69. Amgen, Inc Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 70. Amgen, Inc Recent Developments
Table 71. AstraZeneca, Plc Company Details
Table 72. AstraZeneca, Plc Business Overview
Table 73. AstraZeneca, Plc Immuno-oncology Drugs Product
Table 74. AstraZeneca, Plc Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 75. AstraZeneca, Plc Recent Developments
Table 76. Bristol-Myers Squibb Company Details
Table 77. Bristol-Myers Squibb Business Overview
Table 78. Bristol-Myers Squibb Immuno-oncology Drugs Product
Table 79. Bristol-Myers Squibb Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 80. Bristol-Myers Squibb Recent Developments
Table 81. Celgene Corporation Company Details
Table 82. Celgene Corporation Business Overview
Table 83. Celgene Corporation Immuno-oncology Drugs Product
Table 84. Celgene Corporation Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 85. Celgene Corporation Recent Developments
Table 86. Eli Lilly and Company Company Details
Table 87. Eli Lilly and Company Business Overview
Table 88. Eli Lilly and Company Immuno-oncology Drugs Product
Table 89. Eli Lilly and Company Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 90. Eli Lilly and Company Recent Developments
Table 91. Merck & Co. Company Details
Table 92. Merck & Co. Business Overview
Table 93. Merck & Co. Immuno-oncology Drugs Product
Table 94. Merck & Co. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 95. Merck & Co. Recent Developments
Table 96. Hoffmann-La Roche AG Company Details
Table 97. Hoffmann-La Roche AG Business Overview
Table 98. Hoffmann-La Roche AG Immuno-oncology Drugs Product
Table 99. Hoffmann-La Roche AG Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 100. Hoffmann-La Roche AG Recent Developments
Table 101. Johnson & Johnson Company Details
Table 102. Johnson & Johnson Business Overview
Table 103. Johnson & Johnson Immuno-oncology Drugs Product
Table 104. Johnson & Johnson Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 105. Johnson & Johnson Recent Developments
Table 106. Novartis International AG Company Details
Table 107. Novartis International AG Business Overview
Table 108. Novartis International AG Immuno-oncology Drugs Product
Table 109. Novartis International AG Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 110. Novartis International AG Recent Developments
Table 111. AbbVie, Inc. Company Details
Table 112. AbbVie, Inc. Business Overview
Table 113. AbbVie, Inc. Immuno-oncology Drugs Product
Table 114. AbbVie, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 115. AbbVie, Inc. Recent Developments
Table 116. Pfizer Inc. Company Details
Table 117. Pfizer Inc. Business Overview
Table 118. Pfizer Inc. Immuno-oncology Drugs Product
Table 119. Pfizer Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 120. Pfizer Inc. Recent Developments
Table 121. Sanofi S.A. Company Details
Table 122. Sanofi S.A. Business Overview
Table 123. Sanofi S.A. Immuno-oncology Drugs Product
Table 124. Sanofi S.A. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 125. Sanofi S.A. Recent Developments
Table 126. EMD Serono, Inc. Company Details
Table 127. EMD Serono, Inc. Business Overview
Table 128. EMD Serono, Inc. Immuno-oncology Drugs Product
Table 129. EMD Serono, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 130. EMD Serono, Inc. Recent Developments
Table 131. Gilead Sciences Inc. Company Details
Table 132. Gilead Sciences Inc. Business Overview
Table 133. Gilead Sciences Inc. Immuno-oncology Drugs Product
Table 134. Gilead Sciences Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 135. Gilead Sciences Inc. Recent Developments
Table 136. Prometheus Therapeutics & Diagnostics Company Details
Table 137. Prometheus Therapeutics & Diagnostics Business Overview
Table 138. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product
Table 139. Prometheus Therapeutics & Diagnostics Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 140. Prometheus Therapeutics & Diagnostics Recent Developments
Table 141. Aduro BioTech Company Details
Table 142. Aduro BioTech Business Overview
Table 143. Aduro BioTech Immuno-oncology Drugs Product
Table 144. Aduro BioTech Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 145. Aduro BioTech Recent Developments
Table 146. Galena Biopharma Company Details
Table 147. Galena Biopharma Business Overview
Table 148. Galena Biopharma Immuno-oncology Drugs Product
Table 149. Galena Biopharma Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 150. Galena Biopharma Recent Developments
Table 151. Bavarian Nordic Company Details
Table 152. Bavarian Nordic Business Overview
Table 153. Bavarian Nordic Immuno-oncology Drugs Product
Table 154. Bavarian Nordic Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 155. Bavarian Nordic Recent Developments
Table 156. Celldex Therapeutics Company Details
Table 157. Celldex Therapeutics Business Overview
Table 158. Celldex Therapeutics Immuno-oncology Drugs Product
Table 159. Celldex Therapeutics Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 160. Celldex Therapeutics Recent Developments
Table 161. ImmunoCellular Therapeutics Company Details
Table 162. ImmunoCellular Therapeutics Business Overview
Table 163. ImmunoCellular Therapeutics Immuno-oncology Drugs Product
Table 164. ImmunoCellular Therapeutics Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 165. ImmunoCellular Therapeutics Recent Developments
Table 166. Incyte Company Details
Table 167. Incyte Business Overview
Table 168. Incyte Immuno-oncology Drugs Product
Table 169. Incyte Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 170. Incyte Recent Developments
Table 171. Dendreon Corporation Company Details
Table 172. Dendreon Corporation Business Overview
Table 173. Dendreon Corporation Immuno-oncology Drugs Product
Table 174. Dendreon Corporation Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 175. Dendreon Corporation Recent Developments
Table 176. Agilent Technologies Inc. Company Details
Table 177. Agilent Technologies Inc. Business Overview
Table 178. Agilent Technologies Inc. Immuno-oncology Drugs Product
Table 179. Agilent Technologies Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 180. Agilent Technologies Inc. Recent Developments
Table 181. Agenus Inc. Company Details
Table 182. Agenus Inc. Business Overview
Table 183. Agenus Inc. Immuno-oncology Drugs Product
Table 184. Agenus Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 185. Agenus Inc. Recent Developments
Table 186. Enzo Biochem, Inc. Company Details
Table 187. Enzo Biochem, Inc. Business Overview
Table 188. Enzo Biochem, Inc. Immuno-oncology Drugs Product
Table 189. Enzo Biochem, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 190. Enzo Biochem, Inc. Recent Developments
Table 191. Lonza Group Company Details
Table 192. Lonza Group Business Overview
Table 193. Lonza Group Immuno-oncology Drugs Product
Table 194. Lonza Group Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 195. Lonza Group Recent Developments
Table 196. Bio-Rad Laboratories, Inc. Company Details
Table 197. Bio-Rad Laboratories, Inc. Business Overview
Table 198. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product
Table 199. Bio-Rad Laboratories, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 200. Bio-Rad Laboratories, Inc. Recent Developments
Table 201. Avantor, Inc. Company Details
Table 202. Avantor, Inc. Business Overview
Table 203. Avantor, Inc. Immuno-oncology Drugs Product
Table 204. Avantor, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 205. Avantor, Inc. Recent Developments
Table 206. Spring Bank Pharmaceuticals, Inc. Company Details
Table 207. Spring Bank Pharmaceuticals, Inc. Business Overview
Table 208. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product
Table 209. Spring Bank Pharmaceuticals, Inc. Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 210. Spring Bank Pharmaceuticals, Inc. Recent Developments
Table 211. Ferring Pharmaceuticals Company Details
Table 212. Ferring Pharmaceuticals Business Overview
Table 213. Ferring Pharmaceuticals Immuno-oncology Drugs Product
Table 214. Ferring Pharmaceuticals Revenue in Immuno-oncology Drugs Business (2018-2024) & (US$ Million)
Table 215. Ferring Pharmaceuticals Recent Developments
Table 216. Research Programs/Design for This Report
Table 217. Key Data Information from Secondary Sources
Table 218. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Immuno-oncology Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Immuno-oncology Drugs Market Share by Type: 2022 VS 2029
Figure 3. Immune Checkpoint Inhibitors Features
Figure 4. Immune System Modulators Features
Figure 5. Cancer Vaccines Features
Figure 6. Oncolytic Virus Features
Figure 7. Others Features
Figure 8. Global Immuno-oncology Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Immuno-oncology Drugs Market Share by Application: 2022 VS 2029
Figure 10. Hospitals Case Studies
Figure 11. Clinics Case Studies
Figure 12. Ambulatory Surgical Centers Case Studies
Figure 13. Immuno-oncology Drugs Report Years Considered
Figure 14. Global Immuno-oncology Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Immuno-oncology Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Immuno-oncology Drugs Market Share by Region: 2022 VS 2029
Figure 17. Global Immuno-oncology Drugs Market Share by Players in 2022
Figure 18. Global Top Immuno-oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Immuno-oncology Drugs Revenue in 2022
Figure 20. North America Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Immuno-oncology Drugs Market Share by Type (2018-2029)
Figure 22. North America Immuno-oncology Drugs Market Share by Application (2018-2029)
Figure 23. North America Immuno-oncology Drugs Market Share by Country (2018-2029)
Figure 24. United States Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Immuno-oncology Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Immuno-oncology Drugs Market Share by Type (2018-2029)
Figure 28. Europe Immuno-oncology Drugs Market Share by Application (2018-2029)
Figure 29. Europe Immuno-oncology Drugs Market Share by Country (2018-2029)
Figure 30. Germany Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Immuno-oncology Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Immuno-oncology Drugs Market Share by Type (2018-2029)
Figure 38. China Immuno-oncology Drugs Market Share by Application (2018-2029)
Figure 39. Asia Immuno-oncology Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Immuno-oncology Drugs Market Share by Type (2018-2029)
Figure 41. Asia Immuno-oncology Drugs Market Share by Application (2018-2029)
Figure 42. Asia Immuno-oncology Drugs Market Share by Region (2018-2029)
Figure 43. Japan Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Immuno-oncology Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Immuno-oncology Drugs Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Immuno-oncology Drugs Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Immuno-oncology Drugs Market Share by Country (2018-2029)
Figure 53. Brazil Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Immuno-oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Amgen, Inc Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 60. AstraZeneca, Plc Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 62. Celgene Corporation Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 63. Eli Lilly and Company Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 64. Merck & Co. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 65. Hoffmann-La Roche AG Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 66. Johnson & Johnson Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 67. Novartis International AG Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 68. AbbVie, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 69. Pfizer Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 70. Sanofi S.A. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 71. EMD Serono, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 72. Gilead Sciences Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 73. Prometheus Therapeutics & Diagnostics Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 74. Aduro BioTech Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 75. Galena Biopharma Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 76. Bavarian Nordic Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 77. Celldex Therapeutics Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 78. ImmunoCellular Therapeutics Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 79. Incyte Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 80. Dendreon Corporation Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 81. Agilent Technologies Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 82. Agenus Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 83. Enzo Biochem, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 84. Lonza Group Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 85. Bio-Rad Laboratories, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 86. Avantor, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 87. Spring Bank Pharmaceuticals, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 88. Ferring Pharmaceuticals Revenue Growth Rate in Immuno-oncology Drugs Business (2018-2024)
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries